Novel Peptide Nanofilaments Boost Vaccine Delivery Efficacy
Background
Effective antigen delivery is crucial for developing potent vaccines and immunotherapies. Traditional vaccine formulations often suffer from rapid degradation of antigens, poor cellular uptake, and insufficient immune stimulation, leading to suboptimal immune responses. Nanomaterials, particularly those self-assembled from peptides, offer a promising solution due to their biocompatibility, biodegradability, and tunable properties. However, the comparative efficacy and stability of different peptide architectures, specifically amphiphilic peptides (peptides with both water-attracting and water-repelling parts) versus β-peptides (peptides with modified backbones that enhance stability), as antigen delivery vehicles remain underexplored. This study aims to directly compare the performance of synthetic nanofilaments derived from these two distinct peptide classes for enhancing antigen presentation and immune activation.
Study Design
Results
In vitro, both nanofilament types significantly enhanced antigen uptake by dendritic cells compared to free OVA, with BPNFs showing a 2.8-fold higher uptake than APNFs (p<0.001). In vivo, mice immunized with nanofilament-encapsulated OVA exhibited markedly stronger humoral and cellular immune responses. The β-peptide nanofilaments (BPNFs) group demonstrated the most robust immune activation, inducing 43% higher anti-OVA IgG antibody titers and a 3.5-fold increase in OVA-specific CD8+ T-cell proliferation compared to the APNF group (p<0.01 for both). Furthermore, BPNFs maintained antigen integrity for 72 hours in serum, a 2.1-fold improvement over APNFs, suggesting superior stability. This enhanced stability and cellular delivery translated into a 95% seroconversion rate in the BPNF group, compared to 78% for APNFs and only 20% for free OVA.
Why It Matters
This study highlights the significant potential of β-peptide nanofilaments as superior antigen delivery systems, offering enhanced stability and immunogenicity compared to conventional amphiphilic peptide structures. The robust immune responses observed suggest that these novel nanostructures could overcome key limitations of current vaccine platforms, potentially leading to more effective and durable protection against infectious diseases or even cancer. The findings provide a strong foundation for the development of next-generation peptide-based vaccines and immunotherapies. Further preclinical validation and eventual human clinical trials are warranted to translate these promising results into tangible health benefits.